Literature DB >> 21455196

Papillary thyroid carcinoma: an update.

Virginia A LiVolsi1.   

Abstract

The past two decades have seen numerous developments in the understanding of the origins and biology of papillary thyroid carcinoma. Advances in molecular biology, clinicopathologic studies of new entities, facility with fine-needle aspiration biopsy, and new radiologic imaging techniques have allowed for earlier diagnosis of these tumors. However, these advances have also caused controversies in cytologic and histopathologic diagnoses as well as therapy decisions. This paper will focus on several pathologic aspects of papillary carcinoma, which impact on its biology and prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21455196     DOI: 10.1038/modpathol.2010.129

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  91 in total

1.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

2.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

3.  Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis.

Authors:  Jie Kang; Xian-Zhao Deng; You-Ben Fan; Bo Wu
Journal:  Tumour Biol       Date:  2014-04-24

4.  Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.

Authors:  Ruyi Zhang; Mei Xu; Xiangxiang Liu; Miao Wang; Qiang Jia; Shen Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Yaguang Fan; Heng Wu; Ke Xu; Dihua Li; Zhaowei Meng
Journal:  Endocrine       Date:  2021-04-06       Impact factor: 3.633

5.  BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI).

Authors:  Hong Xie; Bojun Wei; Hong Shen; Ying Gao; Lingling Wang; Hui Liu
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

6.  Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.

Authors:  Yanping Wang; Heather Hardin; Ying-Hsia Chu; Karla Esbona; Ranran Zhang; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

7.  Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma.

Authors:  Yang Guang; Yukun Luo; Yan Zhang; Mingbo Zhang; Nan Li; Ying Zhang; Jie Tang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-24       Impact factor: 4.553

8.  Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Authors:  David F Schneider; Dawn Elfenbein; Ricardo V Lloyd; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

9.  MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Authors:  Ranran Zhang; Heather Hardin; Wei Huang; Jidong Chen; Sofia Asioli; Alberto Righi; Francesca Maletta; Anna Sapino; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

10.  Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis.

Authors:  De-Feng Chang; Zhong-Qing Xu; Bin Sun
Journal:  Tumour Biol       Date:  2014-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.